Clinical data
Trade names Enablex
AHFS/Drugs.com Monograph
MedlinePlus a605039
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
ATC code G04BD10 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability 15 to 19% (dose-dependent)
Protein binding 98%
Metabolism Hepatic (CYP2D6- and CYP3A4-mediated)
Biological half-life 13 to 19 hours
Excretion Renal (60%) and biliary (40%)
CAS Number 133099-04-4 YesY
PubChem (CID) 444031
DrugBank DB00496 YesY
ChemSpider 392054 YesY
KEGG D01699 N
ChEBI CHEBI:391960 YesY
ECHA InfoCard 100.118.382
Chemical and physical data
Formula C28H30N2O2
Molar mass 426.55 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Darifenacin (trade name Enablex in US and Canada, Emselex in Europe) is a medication used to treat urinary incontinence. It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and used to be marketed by Novartis. In 2010 the US rights were sold to Warner Chilcott for 400 million US$.

Mechanism of action

Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.

It should not be used in people with urinary retention. Anticholinergic agents, such as darifenacin, may also produce constipation and blurred vision. Heat prostration (due to decreased sweating) can occur when anticholinergics such as darifenacin are used in a hot environment.[1]

Clinical uses

Darifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency in adults.


This article is issued from Wikipedia - version of the 4/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.